Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: TheSlowLane who wrote (479)	11/9/1998 7:49:00 PM
From: Anthony Wong	Respond to of 2539

Paul, it's strange the way these Wall Street analysts tend to associate drugs developed by biotechs but marketed by big pharmaceuticals as belonging to the big pharmas e.g. ReoPro as LLY's drug rather than Centocor's. However, Pfizer is a formidable marketing machine and Celebrex's brand name recognition could be built up more quickly.

To: TheSlowLane who wrote (479)	11/9/1998 8:17:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

FDA ARTHRITIS ADVISORY COMMITTEE meeting: DATE AND TIME: Dec. 1, and 2, 8 a.m. LOCATION: Town Center Hotel, The Maryland Ballroom, 8727 Colesville Rd., Silver Spring, MD. CONTACT: Kathleen Reedy or LaNise Giles, Center for Drug Evaluation and Research, 301-827-7001. The Committee will discuss Celebrex (celecoxib, Searle) for the treatment of acute or chronic signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of pain. On Dec. 2, from 8 a.m. to 4 p.m. the meeting will be closed to permit review of confidential information. fda.gov